Eylea bayer regeneron?

Question

Accepted Answer

Eylea® (aflibercept)
Co‑marketed by Bayer and Regeneron

Feature	Details
Active ingredient	Aflibercept, a recombinant fusion protein that acts as a “trap” for vascular endothelial growth factor (VEGF).
Formulations	0.5 mg/0.05 mL ophthalmic solution in pre‑filled syringes for intravitreal injection.
FDA‑approved indications	• Neovascular (wet) age‑related macular degeneration (AMD) • Diabetic macular edema (DME) • Macular edema secondary to retinal vein occlusion (RVO) (central, branch)
Typical dosing	• 0.5 mg intravitreal injection: 3 monthly injections, then maintenance every 4–8 weeks (often every 8 weeks after 3–6 months of monthly dosing). • Dosing schedule may be tailored to the patient’s response.
Mechanism of action	Aflibercept binds VEGF‑A, VEGF‑B, and placental growth factor (PlGF), preventing them from stimulating new, leaky blood vessels in the eye.
Common side‑effects	• Injection‑site pain, redness, or swelling • Mild eye pressure increase • Transient blurred vision • Rarely, intraocular inflammation or infection
Serious risks	• Endophthalmitis (infection inside the eye) • Retinal detachment • Systemic vascular events (stroke, heart attack) are rare but have been reported; patients with cardiovascular risk factors should be monitored.
Contraindications	• Known hypersensitivity to aflibercept or any component of the formulation • Active ocular infection or inflammation at the injection site
Drug interactions	• No major systemic interactions are known because the drug is injected directly into the eye. • Concomitant intravitreal steroids or anti‑VEGF agents can be used but should be coordinated by the treating ophthalmologist.
Special populations	• Pregnancy: Category C; use only if clearly needed. • Pediatric: Not approved for ages <12.
Patient counseling	• Report any sudden visual changes, pain, or redness. • Keep scheduled follow‑up appointments for monitoring. • Do not self‑inject; always use sterile technique under professional supervision.

Quick Take‑away

Eylea is a once‑monthly (then often every 8 weeks) eye injection that helps keep vision stable or improve it in people with wet AMD, diabetic or vein‑occlusion macular edema. It works by neutralizing VEGF, the protein that drives abnormal blood‑vessel growth in the retina. While it’s generally well tolerated, eye‑related side‑effects and rare systemic risks exist, so regular eye‑doctor follow‑ups are essential. Always use Eylea under a qualified ophthalmologist’s care.

Ask Questions, Get Industry Insights … Instantly

Recent Questions

Eylea bayer regeneron?

Quick Take‑away